Rituximab as First-line Therapy for Severe Pemphigus: A Case Series and Review of Current Literature
Malaysian Journal of Dermatology
; : 70-76, 2021.
Article
en En
| WPRIM
| ID: wpr-961862
Biblioteca responsable:
WPRO
ABSTRACT
Summary@#Pemphigus refers to a group of life-threatening, autoimmune blistering disease that presents as blisters and erosions involving the skin and mucosa. Systemic corticosteroids and rituximab have been recommended as mainstay therapy for pemphigus vulgaris and pemphigus foliaceus. Herein, we report three cases of pemphigus vulgaris and a case of pemphigus foliaceus treated with rituximab as first-line therapy.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Pénfigo
/
Rituximab
Idioma:
En
Revista:
Malaysian Journal of Dermatology
Año:
2021
Tipo del documento:
Article